Clinical trials
Chronic Liver Disease clinical trials
Below are recruiting chronic liver disease clinical trials, each written for real people, not researchers. We’re tracking 388 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05195450Recruiting
Tenofovir to stop liver disease in mild hepatitis B
This trial tests tenofovir alafenamide (a hepatitis B antiviral medicine) to see if it can prevent liver disease from getting worse in people with chronic hepatitis B who currently have stable (normal) liver blood tests and low virus levels. It may help lower the chance of developing serious liver complications over time.
New Delhi, National Capital Territory of DelhiAges 18–70 - NCT05679024RecruitingPhase 3
Apixaban to prevent stroke in atrial fibrillation and kidney failure
This trial tests apixaban (a blood thinner) to prevent stroke in people with atrial fibrillation or atrial flutter who have very poor kidney function or are on dialysis. If you qualify, you may help researchers find a safer way to lower stroke risk for this higher-risk group.
HelsinkiAges 18 years+ - NCT07487727RecruitingPhase 3
Study of an experimental anemia drug for chronic kidney disease patients not on dialysis
This trial tests an oral medication (AND017) for anemia caused by chronic kidney disease. It aims to improve red blood cell levels without needing dialysis or current anemia treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06971874Recruiting
Sleep apnea and kidney disease: A study on outcomes
This trial looks at how obstructive sleep apnea affects people with chronic kidney disease (stages 3-4). It aims to help understand the connection between these conditions and guide better care.
Guangzhou, GuangdongAges 18–75 - NCT06704516RecruitingPhase 1
HRT and fatty liver disease in menopausal women – a pilot study
This study tests whether starting hormone replacement therapy (HRT) improves liver health in women with menopause and fatty liver disease (MASLD). It aims to understand how HRT might help reduce fat in the liver.
Oxford, OxfordshireAges 18 years+ - NCT07285122RecruitingPhase 1
Inhaled study drug for healthy smokers and people with COPD
This study tests an inhaled medication called RB042 in healthy adults, healthy smokers, and people with COPD. It aims to see how the drug works in the body and whether it is safe, which could help in developing a new treatment for COPD.
Nedlands, Western AustraliaAges 18–80 - NCT06585774RecruitingPhase 3
Axatilimab plus steroids for new chronic GVHD
This study tests a new drug called axatilimab combined with steroids as a first treatment for chronic graft-versus-host disease (GVHD) after a stem cell transplant. It aims to see if this combination helps control symptoms better than steroids alone.
Birmingham, AlabamaAges 12 years+ - NCT07347275Recruiting
Liver dialysis for severe acute-on-chronic liver failure
This trial tests a new liver dialysis device called DIALIVE 2.0 for people with acute-on-chronic liver failure (a sudden, severe worsening of chronic liver disease). If you qualify, the device will help filter your blood, similar to kidney dialysis, to support your liver while it tries to recover.
London, Greater LondonAges 18–70 - NCT06717828Recruiting
Tai Chi for fatty liver in older adults
This trial tests whether Tai Chi, a gentle exercise, can improve fatty liver disease in middle-aged and older adults who are overweight. If you are between 40 and 75 and have metabolic fatty liver, you might be able to join.
Fuzhou, FujianAges 40–75 - NCT07330830Recruiting
Genetics and fatty liver disease in Caribbean and Indian Ocean populations
This study looks at how a specific gene (PNPLA3) might affect non-alcoholic fatty liver disease (MASLD) in people from Guadeloupe, French Guiana, and Réunion Island. It aims to understand genetic differences that could explain why some people get the disease.
CayenneAges 18 years+ - NCT03884075RecruitingPhase 2
Semaglutide study for fatty liver and how sugar affects the liver
This Phase 2 study tests how semaglutide (a diabetes medication also used for weight) affects fatty liver and the liver’s response to sugar. It may help people with non-alcoholic fatty liver disease understand whether the drug improves liver fat and related changes.
Bethesda, MarylandAges 18–100 - NCT05554224Recruiting
Personalized treatment based on obesity-related fatty liver tests
This study uses multiple types of health data (“multi-omics”) to help choose a personalized treatment plan for people with obesity-related fatty liver disease. It may help match treatment to your biology to improve outcomes.
Reus, TarragonaAges 18 years+ - NCT06836609RecruitingPhase 1/Phase 2
Study of a new drug for fatty liver disease (MASLD/MASH)
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
Chandler, ArizonaAges 18–65 - NCT07652151Recruiting
Fatty Liver Disease Study Using Wearable Tracking
This research studies fatty liver disease linked to metabolic problems like diabetes and obesity. You'll wear a fitness tracker and have liver imaging to help doctors understand the disease and find new treatments.
RomaAges 18 years+ - NCT07603817Recruiting
Thyroid Disease and Fatty Liver Disease Study
This study looks at the connection between thyroid problems (especially when the thyroid doesn't make enough hormone) and a common liver condition where fat builds up in the liver. Researchers want to understand how these two conditions relate to each other in people without diabetes.
Sohag, Sohag GovernorateAges 18 years+ - NCT07355868RecruitingEarly Phase 1
Cell therapy for COPD
This trial is testing a new type of cell therapy called REGEND007 for people with COPD. It looks at whether the treatment can help improve how far you can walk and your overall breathing.
Yiwu, ZhejiangAges 40–80 - NCT06152250Recruiting
Fatty liver inflammation study with liver biopsy
This study looks at how the liver's immune environment changes in people with non-alcoholic fatty liver disease (NAFLD) that has progressed to significant scarring. Researchers will use a liver biopsy to understand the inflammation better, which may lead to new treatments.
Lyon, Auvergne-Rhône-AlpesAges 18 years+ - NCT07619157RecruitingPhase 1
ONO-3310 Study for Kidney Disease and Type 2 Diabetes
This early-stage trial tests a new drug called ONO-3310 in two groups: healthy adults and people with kidney disease caused by type 2 diabetes. The study aims to understand how the drug works and whether it might help protect kidney function in people with diabetes.
Fukuoka, FukuokaAges 18–64 - NCT07494409RecruitingPhase 3
A new oral medicine for anemia in dialysis patients
This trial tests a new oral medicine (AND017) for people on dialysis who have anemia (low red blood cells). It may help reduce the need for injections of standard anemia medicines.
ShanghaiAges 18–75 - NCT07242222RecruitingPhase 1/Phase 2
Erdosteine for non-alcoholic fatty liver disease
This trial tests whether a medicine called erdosteine can help treat non-alcoholic fatty liver disease (a condition where extra fat builds up in the liver, not caused by alcohol). It is for adults who have fatty liver confirmed by ultrasound and who do not have other serious health problems.
TantaAges 18–60 - NCT07238985RecruitingPhase 1/Phase 2
Cilostazol for treating nonalcoholic fatty liver disease
This study tests whether a medicine called cilostazol can help treat nonalcoholic fatty liver disease. It is for adults who have fatty liver seen on an ultrasound and do not have other liver problems.
Damietta, New DamiettaAges 18–60 - NCT07781124Recruiting
Remote monitoring for kidney dialysis patients
This study compares the effectiveness and resource use of remote patient monitoring across different dialysis methods for people with end-stage renal disease. It aims to see if remote monitoring can improve care and outcomes.
Beijing, Beijing MunicipalityAges 18–79 - NCT07662889Enrolling by invitation
Comparing two types of dialysis for kidney failure
This trial compares a newer type of dialysis called hemodiafiltration with standard hemodialysis to see if it improves certain health measures in people with end-stage kidney disease. It may help determine which method works better for long-term treatment.
Lahore, Punjab ProvinceAges 18–70 - NCT07646197Recruiting
Peanut Consumption and Fatty Liver Disease in Adults
This study tests whether eating peanuts regularly can help improve fatty liver disease (a condition where fat builds up in the liver). You'll be asked to eat peanuts as part of your diet while researchers track changes in your liver health.
Detroit, MichiganAges 30–70
Hear when a new Chronic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic liver disease?
- Yes. Clin2 currently lists 388 recruiting chronic liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.